Immunogen Inc. has enough cash – almost – to reach the phase III readout with antibody-drug conjugate (ADC) mirvetuximab soravtansine (mirv) in ovarian cancer, thanks to the option deal for earlier-stage ADCs with Jazz Pharmaceuticals plc, which paid $75 million up front.